Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological MonitoringReportar como inadecuado




Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

The most recent World Health Organization WHO antiretroviral treatment guidelines recommend the inclusion of zidovudine ZDV or tenofovir TDF in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

Methods

We used a stochastic simulation of a generalized HIV-1 epidemic in sub-Saharan Africa to compare two strategies for first-line combination antiretroviral treatment including lamivudine, nevirapine and either ZDV or TDF. Model input parameters were derived from literature and, for the simulation of resistance pathways, estimated from drug resistance data obtained after first-line treatment failure in settings without virological monitoring. Treatment failure and cost effectiveness were determined based on WHO definitions. Two scenarios with optimistic no emergence; base and pessimistic extensive emergence assumptions regarding occurrence of multidrug resistance patterns were tested.

Results

In the base scenario, cumulative proportions of treatment failure according to WHO criteria were higher among first-line ZDV users median after six years 36% 95% simulation interval 32%; 39% compared with first-line TDF users 31% 29%; 33%. Consequently, a higher proportion initiated second-line therapy including lamivudine, boosted protease inhibitors and either ZDV or TDF in the first-line ZDV user group 34% 31%; 37% relative to first-line TDF users 30% 27%; 32%. At the time of second-line initiation, a higher proportion 16% of first-line ZDV users harboured TDF-resistant HIV compared with ZDV-resistant viruses among first-line TDF users 0% and 6% in base and pessimistic scenarios, respectively. In the base scenario, the incremental cost effectiveness ratio with respect to quality adjusted life years QALY was US$83 when TDF instead of ZDV was used in first-line therapy pessimistic scenario: US$ 315, which was below the WHO threshold for high cost effectiveness US$ 2154.

Conclusions

Using TDF instead of ZDV in first-line treatment in resource-limited settings is very cost-effective and likely to better preserve future treatment options in absence of virological monitoring.



Autor: Viktor von Wyl , Valentina Cambiano, Michael R. Jordan, Silvia Bertagnolio, Alec Miners, Deenan Pillay, Jens Lundgren, Andrew N.

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados